Table 1 characteristics of patients in two groups
From: Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
| Â | Test group | Control group |
|---|---|---|
Number of patients | 121 | 108 |
Age range (mean standard deviation) | ||
   male | 40-73(54 ± 9.23) | 41-74(54.5 ± 10.33) |
   female | 27-68(48.25 ± 12.70) | 18-67(49.58 ± 12.12) |
Gender | Â | Â |
   Male | 72 (59.50%) | 65 (60.20%) |
   Female | 49 (40.50%) | 43 (39.80%) |
Drug | ||
   Cisplain(75 mg/m2) | 56 (46.30%) | 44 (40.70%) |
   Oxaliplatin(85 mg/m2) | 27 (22.30%) | 26 (24.10%) |
   Epirubicin(90 mg/m2) | 19 (15.7%) | 22 (20.4%) |
   Carboplatin(AUC 5) | 9 (7.40%) | 4 (3.7%) |
   Adriamycin(50 mg/m2) | 10 (8.3%) | 10 (9.3%) |
   Dacarbazine(200 mg/m2) | 0 | 2(1.9%) |
Cancer type | ||
   Lung | 39 | 15 |
   Stomach | 9 | 12 |
   Breast | 23 | 31 |
   Ovarian | 10 | 2 |
   Lymphoma | 12 | 10 |
   Oesophageal | 5 | 6 |
   Colorectal | 16 | 14 |
   Oropharyngeal | 3 | 0 |
   Teratoma | 4 | 0 |
   Gingival | 0 | 3 |
   Thymus | 0 | 4 |
   Cervical | 0 | 4 |
   Laryngeal | 0 | 2 |
   Malignant melanoma | 0 | 3 |
   Glioblastoma | 0 | 2 |